None listed
Conditions
Brief summary
What is the purpose of this study? The purpose is to investigate the possible role of specialised imaging called Sestamibi SEPC/CT in the diagnosis of renal masses. Who is it for? You are eligible to participate in this study if you are an adult that has had a renal mass detected and are scheduled to undergo a renal biopsy in the near future. Study details All willing and suitable participants will undergo specialised imaging involving a scan that takes approximately 45 minutes. The results of the imaging study will be compared with the results of the renal biopsy to be arranged as per normal by the patients urologist. If proven to be effective in its ability to differentiate renal oncocytomas from renal cell carcinoma the sestamibi imaging technique could be more frequently used in the standard investigation of renal masses detected on abdominal imaging. In doing so the number of invasive renal biopsies may decline.
Interventions
99m Tc-Sestamibi SPEC/CT is a nuclear imaging study used to investigate ischaemic heart disease and parathyroid nodules. Recently its use in renal mass imaging has increased as early research has shown its ability to help differentiate benign renal oncocytomas from malignant renal cell carcinomas.
Brand Name of 99m Tc-Sestamibi Tracer - Cardiolite
Dose administered to patient is 925 MBq
Effective radioactivity dose to patient is 5.32 mSv (with CT)
75-95 minutes must pass prior to imaging to
99m Tc-Sestamibi SPEC/CT is a nuclear imaging study used to investigate ischaemic heart disease and parathyroid nodules. Recently its use in renal mass imaging has increased as early research has shown its ability to help differentiate benign renal oncocytomas from malignant renal cell carcinomas. Brand Name of 99m Tc-Sestamibi Tracer - Cardiolite Dose administered to patient is 925 MBq Effective radioactivity dose to patient is 5.32 mSv (with CT) 75-95 minutes must pass prior to imaging to enable effective renal uptake Imaging takes approximately 30 min
Sponsors
Thomas England
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Diagnosis
Masking
Blinded (masking used) (Investigator)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1) Patient with a renal mass detected with an imaging study where the radiological features of the mass make it hard to distinguish between renal cell carcinoma and renal oncocytoma. 2) Patient is scheduled to have a renal biopsy to determine the histopathological diagnosis of the mass in the near future.
Exclusion criteria
Pregnancy Under 18 years of age
Outcome results
None listed